dc55a66962f938562679371f4da76e294a577e8221f1b31b48a86ca837e2f7a9

Sales (USD, millions)

Cost of Sales (USD, millions)

Selling, General and Administrative Expenses (USD, millions)

Research and Development Expenses (USD, millions)

Restructuring Costs (USD, millions)

Other (Income) Expense, Net (USD, millions)

Income Before Taxes (USD, millions)

Taxes on Income (USD, millions)

Net Income (USD, millions)

Net Income Attributable to Noncontrolling Interests (USD, millions)

Net Income Attributable to Merck & Co., Inc. (USD, millions)

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (USD)

d302767b76f5d281915e6d9b73684dbccfc36e733a4a187af698446810d01bf8

Cash and cash equivalents (USD, millions)

Short-term investments (USD, millions)

Accounts receivable (USD, millions)

Inventories (USD, millions)

Other current assets (USD, millions)

Total current assets (USD, millions)

Investments (USD, millions)

Property, Plant and Equipment, net (USD, millions)

Goodwill (USD, millions)

Other Intangibles, Net (USD, millions)

Other Assets (USD, millions)

Total Assets (USD, millions)

Loans payable and current portion of long-term debt (USD, millions)

Trade accounts payable (USD, millions)

Accrued and other current liabilities (USD, millions)

Income taxes payable (USD, millions)

Dividends payable (USD, millions)

Total current liabilities (USD, millions)

Long-Term Debt (USD, millions)

Deferred Income Taxes (USD, millions)

Other Noncurrent Liabilities (USD, millions)

Common stock (USD, millions)

Other paid-in capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total Merck & Co., Inc. stockholders’ equity (Subtotal) (USD, millions)

Less treasury stock, at cost (USD, millions)

Total Merck & Co., Inc. stockholders’ equity (USD, millions)

Noncontrolling Interests (USD, millions)

Total equity (USD, millions)

Total Liabilities and Equity (USD, millions)

e4fcbf015777e125c39cd50b7f17f095eeb510c2b08eb382d859933269a776c2

953d5f08a800b094a8769460f5f03b5e54d3cf936fa77e7223b987d63f1cb8a7

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

24f11be1fbfd9cb2efcb9fa090aa6ff6ba43f17e4cd11be59f42da6aa626a094

Adjustments for Non-Cash Items

Stock-Based Compensation

Changes in Working Capital

Capital Expenditures (CapEx)

Proceeds from Debt

Repayments of Debt

Share Repurchases

Dividend Payments

Net Change in Cash

897024ce5a230257def4f9dc4afe40cbecf2f9643bc96bd1eaf53fbf647e6f17

Number of tumor types for Keytruda in the U.S. (tumor types)

Number of tumor-agnostic indications for Keytruda in the U.S. (indications)

0ab994adad13328a6cef2270ba622f0eabc600ef1d96a5c8e757f14e79fd19f6

b0b59f4b1d5d05ee6bc20b75b2ad24ca5f6ef7bfd9e86b13096909ace22a736e

United States

Europe, Middle East, Africa

- Europe

- Eastern Europe, Middle East, and Africa

China

Japan

Latin America

Asia Pacific

Other

- Canada

Total Revenue

96dd1fd0599265b53fb2458b2da7510325298399fd3c2f671faa840bfb21d5a2

Merck & Co. (MRK)

Financials